VISICORT meeting with Epimune Diagnostics


Epimune (www.epimune-dx.com) and the VISICORT Consortium are interested in entering into a collaboration in the field of diagnosis and monitoring of corneal transplant recipients using epigenetic immune cell quantification. The goal of the collaboration is the exploration of epigenetic immune cell quantification to monitor patients after corneal transplantation and to detect (and potentially predict) adverse events earlier than with currently available methods.

The face to face meeting on Tuesday 10th October 2019 with Dr Christoph Sachsenmeier from Epimune Diagnostics was an opportunity to discuss the collaboration further and to explore new collaborations within the diabetic kidney and ophthalmology research areas.

Pictured L to R: Matt Griffin, Conor Murphy, Joan Ní Gabhann, Christoph Sachsenmeier and Diana Malata at the RCSI, Dublin

Attendees included VISICORT Coordinator Prof. Matt Griffin and Dr Siobhán Gaughan from NUI Galway, VISICORT team members from the Royal College of Surgeons in Ireland PI Prof. Conor Murphy, Dr Joan Ní Gabhann and Diana Malata of the RCSI, the Royal College of Surgeons in Ireland and Dr Christoph Sachsenmeier, the VP Business Development at Epimune.

Epimune’s goal is to revolutionize diagnosis and monitoring of patients with disorders of the immune system.  Epimune develops in vitro diagnostic (IVD) tests using proprietary epigenetic immune cell quantification technology (Baron et al., 2018). This approach allows for broad immune cell profiling from minute sample amounts (e.g. blood – fresh/frozen/dried; other bodily fluids; tissue). Epimune uses proprietary real-time PCR-based assays for quantification of more than 20 different immune cell types.